Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma

Medical Principles and Practice

Volumn 21, Issue 1, 2011, Pages 68-73

  Chen, Dong ^a   Zheng, Xuefeng ^a   Kang, Dalu ^a   Yan, Bomin ^a   Liu, Xiaoyi ^a   Gao, Yuan ^b   Zhang, Kejun ^a  

^a QINGDAO UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2 protein family; P53; Pancreatic ductal adenocarcinoma

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BCL XS; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; PANCREAS ADENOCARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; GENES, BCL-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STATISTICS AS TOPIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82955195889     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000332423     Document Type: Article

References (32)

1. Hunter AM, LaCasse EC, Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-1568. (Pubitemid 47106887)
2. Karnak D, Xu L: Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 2010; 11: 699-707.
3. Löhr JM: Medical treatment of pancreatic cancer. Expert Rev Anticancer Ther 2007; 7: 533-544.
4. Claude L, Mornex F: Chemoradiation in pancreatic carcinoma. Cancer Radiother 2003; 7: 254-265. (Pubitemid 37000057)
5. Yeh JJ, Der CJ: Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 2007; 11: 673-694. (Pubitemid 46730082)
6. Hamacher R, Schmid RM, Saur D, Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 7: 64-70.
7. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R: Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 2010; 10: 1647-1661.
8. Roy SK, Srivastava RK, Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010; 5: 10.
9. Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007; 13: 7254-7263.
10. Roset R, Ortet L, Gil-Gomez G: Role of Bcl-2 family members on apoptosis: what we have learned from knock-out mice. Front Biosci 2007; 12: 4722-4730.
11. Youle RJ, Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
12. Breckenridge DG, Xue D: Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 2004; 16: 647-652. (Pubitemid 39463115)
13. Tsujimoto Y: Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003; 195: 158-167. (Pubitemid 36384290)
14. Hattori T, Ookawa N, Fujita R, Fukuchi K: Heterodimerization of Bcl-2 and Bcl-X(L) with Bax and Bad in colorectal cancer. Acta Oncol 2000; 39: 495-500.
15. Gianni M, Ponzanelli I, Mologni L, Reichert U, Rambaldi A, Terao M, Garattini E: Retinoid- dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells: expression and activation of caspases. Cell Death Differ 2000; 7: 447-460. (Pubitemid 30255713)
16. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW: Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl- 2/Bax. Br J Cancer 2002; 87: 555-561.
17. Casneuf VF, Fonteyne P, Van Damme N: Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest 2008; 26: 852-859.
18. Hashimoto K, Nio Y, Koike M, Itakura M, Yano S, Higami T, Maruyama R: Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome. Anticancer Res 2005; 25: 1361-1368. (Pubitemid 40546816)
19. Geng Y, Walls KC, Ghosh AP, Akhtar RS, Klocke BJ, Roth KA: Cytoplasmic p53 and activated Bax regulate p53-dependent, transcription- independent neural precursor cell apoptosis. J Histochem Cytochem 2010; 58: 265-275.
20. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM: Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001; 20: 240-251. (Pubitemid 32150269)
21. Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake GP, Taylor JA: K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population- based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1223-1232.
22. Horiuchi H, Kawamata H, Omotehara F, Fujii S, Fujimori T, Kuroda Y: Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells. J Gastroenterol 2004; 39: 801-803. (Pubitemid 39264152)
23. Martens U, Stenius U: Immunohistochemical detection of induced expression of wildtype p53 tumor suppressor protein in the livers of rats treated with diethylnitrosamine. Histochem J 1999; 31: 75-78. (Pubitemid 29294794)
24. van Gijssel HE, van Gijlswijk RP, de Haas RR, Stark C, Mulder GJ, Meerman JH: Immunohistochemical visualization of wild-type p53 protein in paraffin-embedded rat liver using tyramide amplification: zonal hepatic distribution of p53 protein after N-hydroxy-2- acetylaminofluorene administration. Carcinogenesis 1998; 19: 219-222. (Pubitemid 28376846)
25. Barakat K, Mane J, Friesen D, Tuszynski J: Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J Mol Graph Model 2010; 28: 555-568.
26. Krepischi-Santos AC, Rajan D, Temple IK, Shrubb V, Crolla JA, Huang S, Beal S, Otto PA, Carter NP, Vianna-Morgante AM, Rosenberg C: Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1. Cytogenet Genome Res 2009; 125: 1-7.
27. Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC, Vose JM, Fu K, Armitage JO, Braziel RM, Campo E, Delabie J, Gascoyne RD, Jaffe ES, Muller-Hermelink HK, Ott G, Rosenwald A, Staudt LM, Im MY, Karaman MW, Pike BL, Chan WC, Hacia JG: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103: 2352-2357. (Pubitemid 43271673)
28. Slee EA, O'Connor DJ, Lu X: To die or not to die: how does p53 decide? Oncogene 2004; 23: 2809-2818. (Pubitemid 38638844)
29. Clarke AR, Purdie CA, Harrison DJ: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852. (Pubitemid 23132162)
30. Sato Y, Nio Y, Song MM: p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997;17: 2779-2788. (Pubitemid 27352687)
31. Dergham ST, Dugan MC, Joshi US: The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Cancer 2002;80: 372-381.
32. Miyashita T, Krajewski S, Krajewska M: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805. (Pubitemid 24163411)